_256_384.jpg)
Drug Approval | April 14, 2024
Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations
This facility manufactures APIs & formulations of oncology and non-oncology products.
This facility manufactures APIs & formulations of oncology and non-oncology products.
A five-day inspection was concluded successfully with no critical and no major observations raised
ANVISA issues CGMP to Concord Biotech’s Unit I
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
Employer-sponsored health insurance costs in India are expected to rise by 11% in 2024
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Sarclisa added to bortezomib, lenalidomide and dexamethasone (VRd) significantly reduced the risk of disease progression or death compared with VRd alone
The companies will work with investigators to share the results with the scientific community
Parecoxib Sodium is the first parenteral selective COX-2 inhibitor available for clinical use in pain management
Our collaboration with MediSage to present 'Current Approaches to Uro-Oncology' embodies a crucial stride towards comprehensive cancer care
Subscribe To Our Newsletter & Stay Updated
